MSI Methylation Sciences Inc.

MSI Methylation Sciences Inc. is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets.

Strada™, our lead product, is targeting Major Depressive Disorder.

NEWS

August 25, 2015 MSI Methylation Sciences Inc. (MSI) Treats the Last Patient in its Horizon Trial and Receives Four Patents to Support its Proprietary Treatment Strada™ for Major Depressive Disorder (MDD) More

May 7, 2015. MSI Methylation Sciences, Inc. (MSI) Completes Recruitment of Phase 2 Trial for its Novel Treatment Strada™ for Major Depressive Disorder (MDD)More